Tariff

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

Retrieved on: 
Friday, December 22, 2023
3Q, Hagens Berman, Lung cancer, SAN, Tariff, Bank statement, Person, Pharmaceutical industry

SAN FRANCISCO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .
  • The company also stated that its failure to deliver its financial statements to its lenders constituted an event of default under its credit agreement.
  • Then, on Nov. 29, 2023, Eagle announced that its board of directors accepted the resignation of its CEO (Scott Tarriff) effective immediately.
  • “We are investigating the propriety of Eagle Pharmaceuticals reserve and price adjustments and the sufficiency of its internal controls over financial reporting,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Eagle Pharmaceuticals (EGRX) Engaged in Accounting Fraud, Investor Suit Alleges - Hagens Berman

Retrieved on: 
Monday, December 18, 2023
Person, News, Hagens Berman, SAN, Tariff, Pharmaceutical industry

SAN FRANCISCO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .
  • Eagle Pharmaceuticals, Inc. (EGRX) Securities Fraud Class Action:
    “The litigation focuses on whether Eagle Pharmaceuticals knew and should have disclosed earlier that it under reserved,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Investors began to learn the truth on Nov. 9, 2023, when Eagle announced that it would not timely file its financial report for the quarter ended Sept. 30, 2023.
  • This news sent the price of Eagle shares down $2.55, or about 31%, on Nov. 29, 2023.

Eagle Pharmaceuticals (EGRX) Engaged in Accounting Fraud, Investor Suit Alleges - Hagens Berman

Retrieved on: 
Thursday, December 14, 2023
Person, News, Hagens Berman, SAN, Tariff, Pharmaceutical industry

SAN FRANCISCO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .
  • Eagle Pharmaceuticals, Inc. (EGRX) Securities Fraud Class Action:
    “The litigation focuses on whether Eagle Pharmaceuticals knew and should have disclosed earlier that it under reserved,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Investors began to learn the truth on Nov. 9, 2023, when Eagle announced that it would not timely file its financial report for the quarter ended Sept. 30, 2023.
  • This news sent the price of Eagle shares down $2.55, or about 31%, on Nov. 29, 2023.

Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq – Hagens Berman

Retrieved on: 
Monday, December 11, 2023
Person, Failure, Hagens Berman, SAN, Tariff, Pharmaceutical industry

SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .
  • “The investigation focuses on the propriety of Eagle Pharmaceuticals revenue recognition practices and the sufficiency of its internal controls over financial reporting,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • On Nov. 9, 2023, Eagle announced that it would not timely file its financial report for the quarter ended Sept. 30, 2023.
  • If you’d like more information and answers to frequently asked questions about the Eagle Pharmaceuticals investigation, read more .

Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors: Please contact the Portnoy Law Firm to recover your losses

Retrieved on: 
Tuesday, December 5, 2023
Tariff, Eagle, Behavior, Employment, Form 10-Q, Pharmaceutical industry

LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Eagle stock. Eagle investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Eagle stock.
  • Eagle investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • On November 9, 2023, Eagle Pharmaceuticals announced a delay in filing their financial report for the quarter ending September 30, 2023.

Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq - Hagens Berman

Retrieved on: 
Monday, December 4, 2023
Failure, Hagens Berman, Person, Tariff, Pharmaceutical industry

“The investigation focuses on the propriety of Eagle Pharmaceuticals revenue recognition practices and the sufficiency of its internal controls over financial reporting,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Key Points: 
  • “The investigation focuses on the propriety of Eagle Pharmaceuticals revenue recognition practices and the sufficiency of its internal controls over financial reporting,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • On Nov. 9, 2023, Eagle announced that it would not timely file its financial report for the quarter ended Sept. 30, 2023.
  • To date, Eagle has not filed its Form 10-Q and has received a notice of deficiency from Nasdaq for its failure to do so.
  • These events sent the price of Eagle shares sharply lower.

Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq - Hagens Berman

Retrieved on: 
Friday, December 1, 2023
Person, Failure, Hagens Berman, SAN, Tariff, Pharmaceutical industry

SAN FRANCISCO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .
  • “The investigation focuses on the propriety of Eagle Pharmaceuticals revenue recognition practices and the sufficiency of its internal controls over financial reporting,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • On Nov. 9, 2023, Eagle announced that it would not timely file its financial report for the quarter ended Sept. 30, 2023.
  • To date, Eagle has not filed its Form 10-Q and has received a notice of deficiency from Nasdaq for its failure to do so.

Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women

Retrieved on: 
Tuesday, August 29, 2023
CMS, The Orange Book, NDA, Fulvestrant, Woman, Medicine, Research, Oncology, Orange Book, Patent, Patient, MBC, Physician, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tariff, Food, Breast cancer, Pharmaceutical industry, IQVIA, Eagle

WOODCLIFF LAKE, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women. EA-114 has the potential to provide healthcare providers with a formulation that meaningfully optimizes the dosing regimen for all fulvestrant patients. Eagle currently anticipates filing a new drug application (“NDA”) for EA-114 in 2024. If approved for all uses, EA-114 would allow physicians to provide a personalized treatment regimen to all patients, including specific sub-populations.

Key Points: 
  • Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women.
  • If approved for all uses, EA-114 would allow physicians to provide a personalized treatment regimen to all patients, including specific sub-populations.
  • Currently, fulvestrant is indicated as monotherapy first-line endocrine treatment in post-menopausal women with hormone receptor-positive metastatic breast cancer (MBC) and in combination therapy to treat hormone receptor positive, advanced breast cancer in women whose breast cancer has spread or worsened after being treated with anti-estrogen medications.
  • Eagle intends to provide additional updates on the progress of the EA-114 development program for the sub-populations as discussions with the FDA progress.

Eagle Pharmaceuticals Reports Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023
Share repurchase, QIDP, Bronchopneumonia, Marketing, Food, Eagle, Type, Acquisition, Patient, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Pemetrexed, Tariff, Safety, Breast cancer, Film industry, Video game, Pharmaceutical industry, Tutoring, Remimazolam

“We delivered a strong second quarter with impressive earnings and revenue, continuing the positive trajectory from an outstanding 18 months of business performance,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.

Key Points: 
  • “We delivered a strong second quarter with impressive earnings and revenue, continuing the positive trajectory from an outstanding 18 months of business performance,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
  • Depending upon recruitment rates, Eagle anticipates having its 50% interim report around the first half of 2024.
  • Total revenue for the second quarter of 2023, was $64.6 million, as compared to $74.1 million for the second quarter of 2022.
  • Second quarter 2023 royalty revenue was $21.7 million, compared to $24.9 million in the prior year quarter.

Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance

Retrieved on: 
Thursday, June 15, 2023
Acacia, Maintenance, Food and Drug Administration Safety and Innovation Act, QIDP, Bronchopneumonia, Marketing, Food, Eagle, Progress, GAIN, Vomiting, Acquisition, Patent, PONV, Patient, Physician, NCE, Nursing, Growth, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Pemetrexed, Tariff, Safety, Breast cancer, Pharmaceutical industry, Remimazolam

“As we approach midyear 2023, our business remains strong, and we are pleased with the positive growth trajectory in our key commercial products. Through our well-trained and experienced sales force -- made up of 50 reps on the hospital side of the business and 25 focused on oncology -- for the quarter to date, Barhemsys® and Byfavo® have already topped the sales number posted in the first quarter of 2023, and PEMFEXY® has achieved an 18% market share in early Q2. We are pleased to see these two assets gaining uptake in the hospital and reflecting the value we saw when we originally decided to make the acquisition,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.

Key Points: 
  • WOODCLIFF LAKE, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial guidance.
  • “As we approach midyear 2023, our business remains strong, and we are pleased with the positive growth trajectory in our key commercial products.
  • Eagle anticipates continued growth in net sales of PEMFEXY in the remainder of 2023 as compared to 2022.
  • Guidance: The Company reaffirms previously provided 2023 full-year guidance.